Our markets
With the overall aim of increasing patient engagement to life-changing treatment and medication, our focus is on long-term conditions, cancer, and rare diseases.
Our mission is to give patients across Europe, control of their health through knowledge, choice, convenience and connection.
Rare diseases & orphan drugs
We’re a global network dedicated to getting rare and orphan medicines to hard-to-reach patients worldwide.
Long-term conditions
As a leading life sciences business, we help those with long-term conditions get the best from their medicines.
Cancer treatments
Delivering a range of treatments, we are the UK’s leading provider of cancer in-home care.
Sciensus Digital+
We elevate patient care by combining advanced digital platforms with a personalised “human touch”.
Delivering vital medicines
Cancer care at home
Increasing European access
Powered by insight
Stay up to date with the news, find out more about our latest developments and learn from experts across Sciensus.
Blogs/Articles
EMA orphan drug designation
Gaining orphan drug designation from the European Medicines Agency (EMA) is essential for any company seeking to market a new…
Blogs/Articles
Four considerations before collecting real-world data in your EAP
Early access programs (EAPs) for rare disease medications present a valuable opportunity for biotechs to collect real-world data (RWD). In…
Blogs/Articles
The increasing importance of real-world data for the EMA
Over recent years, real-world data (RWD) has become a critical element of the development and commercialisation of medications. RWD includes…